Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harmony Biosciences Holdings has the GF Score of 94, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Harmony Biosciences Holdings
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Harmony Biosciences Holdings GF Score Related Terms
HRMY vs SION, URGN, PVLA: GF Score Comparison
For the Biotechnology subindustry, Harmony Biosciences Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's GF Score distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's GF Score falls into.
Harmony Biosciences Holdings (HRMY) has a GF Score of 94 as of Aug. 07, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Harmony Biosciences Holdings and its competitors. This is 84% above median its historical median of 51.00. Over the past decade, Harmony Biosciences Holdings' GF Score has ranged from 10.00 to 94.00.
Is Harmony Biosciences Holdings' GF Score too high?
Harmony Biosciences Holdings' current GF Score of 94 is 84% above median its 10-year median of 51.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 94.00. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' GF Score compare to SION and URGN?
Harmony Biosciences Holdings' GF Score of 94 can be compared against companies in the Biotechnology industry. Historically, Harmony Biosciences Holdings' own GF Score has ranged from 10.00 to 94.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Harmony Biosciences Holdings and its competitors. Harmony Biosciences Holdings's current GF Score is 94, which is 84% above median its own 10-year median of 51.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.93, compared to a current price of $38.74 — trading 17.5% below its estimated fair value. The current GF Score is 94, which is 84% above median its 10-year median of 51.00. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current GF Score is 94 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $38.74 is trading 17.5% below its estimated GF Value™ of $46.93.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
GF Score: 94 (84% above median its 10-year median of 51.00)
GF Value™: $46.93 vs. price of $38.74 (17.5% below fair value)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score
Get the complete analysis for HRMY
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
